Summary：**Abivax Excited by $920M Cash, Prepares Solo U.S. Launch, CEO Reveals**French biotech Abivax announ

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

**Abivax Excited by $920M Cash, Prepares Solo U.S. Launch, CEO Reveals**

French biotech Abivax announced that its latest financing round has secured roughly $920 million in cash, a war chest the company says will sustain operations through 2029. The infusion comes after a series of oversubscribed private placements and strategic partnerships, giving Abivax the financial runway to advance its pipeline without relying on dilutive follow‑on rounds. Chief Executive Officer Hartmut Ehrlich highlighted the milestone during a briefing with investors, noting that the balance sheet now enables the firm to pursue a solo launch of its lead candidate in the United States.

**Key Developments**
The fundraising, led by existing institutional investors and joined by several new healthcare‑focused funds, closed at the upper end of the target range. Abivax earmarked the proceeds for three primary purposes: completing Phase 3 trials for its anti‑inflammatory molecule ABX464, preparing regulatory submissions for the U.S. market, and expanding commercial capabilities in North America. Ehrlich confirmed that the company will forego a co‑promotion deal and instead build its own sales force, a move he described as “a testament to confidence in the data and the therapeutic potential.” The cash cushion also covers general‑and‑administrative expenses, ensuring that research programs in fibrosis and oncology remain fully funded through the end of the decade.

**Industry Analysis**
Analysts note that Abivax’s cash position places it among the best‑funded mid‑stage